Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)

BMC Cancer

Research Article

Justyna Rybka¹  Aleksandra Butrym²  Ryszard Wichary³  Andrzej Mital⁴  Maria Bieniaszewska⁴  Krzysztof Warzocha⁵  Elżbieta Patkowska⁵  Ewa Lech-Maranda⁶  Krzysztof Madry⁷  Tigran Torosian⁷  Grzegorz Mazur⁸  Beata Kumiega⁹ 

[1] Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland;Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland;Department of Physiology, Wroclaw Medical University, Wroclaw, Poland;Department of Hematology and Bone Marrow Transplantation, Silesian Medical University, Katowice, Poland;Department of Hematology and Transplantology, Medical University of Gdansk, Gdansk, Poland;Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland;Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland;Centre of Postgraduate Medical Education, Warsaw, Institute of Hematology and Transfusion Medicine, Warsaw, Poland;Department of Hematology, Warsaw Medical University, Warsaw, Poland;Department of Internal Medicine, Occupational Diseases and Hypertension, Wroclaw Medical University, Wroclaw, Poland;Department of Oncological Hematology, Carpathian Oncology Centre, Brzozow, Poland;

关键词: Myelodysplastic syndrome;    del(5q);    Lenalidomide;    Transfusion independence;   

DOI  :  10.1186/s12885-015-1444-1

 received in 2015-02-10, accepted in 2015-05-18,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundLenalidomide has been approved for the treatment of lower-risk myelodysplastic syndrome (MDS) with 5q deletion (del(5q)). We present for the first time a retrospective analysis of low-risk MDS with isolated del5q treated with lenalidomide, outside the clinical trials.Methods36 red blood cell (RBC) transfusion-dependent patients have been included in the study. Patients received lenalidomide 10 mg/day on days 1–21 of 28-day cycles.Results91.7 % of patients responded to lenalidomide treatment: 72.2 % achieved erythroid response, 19.4 % achieved minor erythroid response and 8.4 % of patients did not respond to treatment. Response depended on number of previous treatment lines (p = 0.0101), International Prognostic System Score (IPSS; p = 0.0067) and RBC transfusion frequency (p = 0.0139). Median duration of response was 16 months (range 6–60 months). Treatment was well tolerated. We observed hematological toxicity (grade 3 and 4): neutropenia in 16 (44.4 %) patients and thrombocytopenia in 9 (25 %) patients. Two patients (5.5 %) progressed to high-risk MDS and two subsequent progressed to acute myeloid leukemia. A Kaplan-Meier estimate for overall survival at 5 years in the study group was 79.0 ± 8.8 %.ConclusionsLenalidomide in this group of patients was beneficial for the treatment of RBC transfusion-dependency with well-known safety profile.

【 授权许可】

CC BY   
© Butrym et al. 2015